Since we sometimes decrease the dosage of dydrogesterone to 10 mg/d when the serum LH level is suppressed below 1.0 mIU/ml, we assume that the optimization or individualization of progestin dosage is necessary, especially for breast cancer cases. The gene discussed is PLOD1; the disease is breast carcinoma.